Classification of KRAS-Activating Mutations and the Implications for Therapeutic Intervention.

ABSTRACT: Members of the family of RAS proto-oncogenes, discovered just over 40 years ago, were among the first cancer-initiating genes to be discovered. Of the three RAS family members, KRAS is the most frequently mutated in human cancers. Despite intensive biological and biochemical study of RAS proteins over the past four decades, we are only now starting to devise therapeutic strategies to target their oncogenic properties. Here, we highlight the distinct biochemical properties of common and rare KRAS alleles, enabling their classification into functional subtypes. We also discuss the implications of this functional classification for potential therapeutic avenues targeting mutant subtypes.

Significance

Efforts in the recent past to inhibit KRAS oncogenicity have focused on kinases that f

SUBMITTER: Johnson C 

PROVIDER: S-EPMC8988514 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature